NANITE AWARDED $1.8M TO DEVELOP AI-DRIVEN GENE THERAPY FOR HIV

Nanite Receives Funding to Employ SAYERTM Platform to Develop Non-Viral Delivery Vehicles to Express Neutralizing Antibodies In Vivo from the Bill & Melinda Gates Foundation

BOSTON, May 8, 2024 /PRNewswire/ — Nanite, Inc. today announced a $1.8M grant from the Bill & Melinda Gates Foundation to design and optimize polymeric delivery vehicles to deliver DNA-encoded therapeutics.

Nanite’s proprietary SAYERTM platform combines AI-driven polymer design with multiplexed in vivo screening to develop best-in-class polymer nanoparticles [PNPs] for tissue-specific delivery. SAYER has demonstrated strong delivery efficiency and high tissue specificity, potentially overcoming limitations of viral vectors and lipid nanoparticles [LNPs]. In the research project funded by the foundation, Nanite will employ the SAYER platform to design and optimize polymeric delivery vehicles to deliver DNA-encoded therapeutics, thereby durably producing therapeutic antibodies in vivo. Success would represent a significant breakthrough in HIV management, particularly in populations with limited access to medical care.

“Nanite’s research, with support from the Gates Foundation, is consequential in discovering safe polymeric nanoparticles for a transformative treatment for HIV,” notes Nanite Chief Business Officer, Thomas X. Neenan, PhD. “One of our long-stated goals is to develop technologies that allow the benefits of gene therapy to be accessible to a wider patient population, particularly in underserved communities. Nanite is dedicated to accelerating the impact of genetic medicine for the treatment of HIV.”

ABOUT NANITE:

Nanite, Inc. is a non-viral gene delivery company developing programmable, tissue-specific polymer nanoparticles (PNPs) for a broad range of modalities and indications. Powered by our AI-driven platform, SAYERTM, Nanite is building the next generation of non-viral delivery vehicles – programmable, targeted, and safe – for a new wave of genetic medicines. SAYER applies state-of-the-art machine learning-methods to combine high-throughput experimental and computational polymer chemistry to design fit-for-purpose delivery vehicles. Nanite is headquartered in Boston, MA. For more information, visit https://nanitebio.com.

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services